Important market success in Asia: Bayer receives approval for Xarelto successor in China
Reading Time: 2 minutes
Strategic milestone: The Chinese authority NMPA approves the anticoagulant Asundexian under the trade name Sunharbo for stroke prevention. Novel mechanism of action: As the first representative of the class of FXIa inhibitors, the drug offers protection against clots without an increased risk of severe bleeding. Operational relief: The market entry strengthens Bayer's pharmaceutical division, which is suffering from significant revenue losses due to patent expirations on Xarelto and Eylea. The Leverkusen-based...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
